An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: Report from a single center of China

Bone Marrow Transplantation

Volumn 47, Issue 8, 2012, Pages 1087-1094

  Huang, J ^a   Zou, D H ^a   Li, Z J ^a   Fu, M W ^a   Xu, Y ^a   Zhao, Y Z ^a   Qi, J Y ^a   Feng, S Z ^a   Liu, B C ^a   Lin, D ^a   Mi, Y C ^a   Han, M Z ^a   Wang, J X ^a   Qiu, L G ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

adolescent; ALL; auto SCT; survival; young adult

Indexed keywords

MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHINA; CHROMOSOME ABERRATION; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GASTROINTESTINAL INFECTION; GINGIVITIS; HEART ARRHYTHMIA; HEMOPTYSIS; HIGH RISK POPULATION; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEPTICEMIA; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84864876956     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.220     Document Type: Article

References (35)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. (Pubitemid 40310185)
2. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813-819. (Pubitemid 350002881)
3. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J et al. Allogenetic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12: 2580-2587. (Pubitemid 24379642)
4. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86: 1619-1628.
5. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients p50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004; 89: 809-817. (Pubitemid 38981340)
6. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104: 3028-3037. (Pubitemid 39507116)
7. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086. (Pubitemid 41185176)
8. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90: 1346-1356. (Pubitemid 41503650)
9. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833. (Pubitemid 351451489)
10. Cornelissen JJ, van der Holt B, Verhoef GE, van0t Veer MB, van Oers MH, Schouten HC et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113: 1375-1382.
11. Fiè re D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on therapy for adult acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 1990-2001. (Pubitemid 23304626)
12. Dhédin N, Dombret H, Thomas X, Lhé ritier V, Boiron JM, Rigal-Huguet F et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 2006; 20: 336-344. (Pubitemid 43148674)
13. Boissel N, Auclerc MF, Lhé ritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780. (Pubitemid 46606434)
14. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48: 254-261. (Pubitemid 46238513)
15. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children0s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646-1654.
16. DeAngelo DJ, Dahlberg S, Silverman LB, Couban S, Amrein PC, Seftel MD et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007; 110: 587 (abstract).
17. Rijneveld AW, van der Holt B, Daenen SMGJ, Biemond BJ, A van de Loosdrecht A, de Weerdt O et al. High dose intensive chemotherapy, as is standard in childhood leukemia, is feasible and efficacious in adult patients with acute lymphoblastic leukemia (ALL) up to the age of 40: results from the Dutch-Belgian HOVON-70 Study. Blood 2009; 114: 323 (abstract).
18. Blaise D, Gaspard MH, Stoppa AM, Michel G, Gastaut JA, Lepeu G et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1990; 5: 7-12. (Pubitemid 20091575)
19. Carey PJ, Proctor SJ, Taylor P, Hamilton PJ. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77: 1593-1598.
20. Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukemia: final results of the international trial UKALL XII/ ECOG2993. Br J Haematol 2010; 148: 80-89.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
22. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for Cancer Cytogenetics.In: Mittelman F (eds). Supplement to an International System for Human Cytogenetic Nomenclature. Karger: Basel, 1991 pp. 1-53.
23. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214. (Pubitemid 11167383)
24. Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325.
25. DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2005, 123-130.
26. Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009; 23: 1033-1042.
27. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196-199.
28. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 147-156.
29. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116: 1165-1176.
30. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010; 115: 1394-1405.
31. Usvasalo A, Elonen E, Saarinen-Pihkala UM, Räty R, Harila-Saari A, Koistinen P et al. Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data. Leuk Res 2010; 34: 1476-1482.
32. Kantarjian H, Thomas D, O0Brien S, Cortes J, Giles F, Jeha S et al. Long-term followup results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801. (Pubitemid 39603187)
33. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51: 50-60.
34. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M et al. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant 2008; 42: 105-112.
35. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post-induction treatment: a report from the children0s oncology group. J Clin Oncol 2009; 27: 5189-5194.